Navigation Links
Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting

immunomodulatory activities without replicating its side effects. In phase 2 clinical trials, CRx-102 demonstrated a powerful anti-inflammatory effect and rapid onset of action in patients with osteoarthritis and rheumatoid arthritis and was generally well tolerated. CRx-102 is being developed in a modified-release commercial formulation for the treatment of multiple immuno-inflammatory diseases.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its strategic development, its product candidates and their clinical potential, its plans for clinical and formulation development of its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candid
'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
8. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
9. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
10. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
11. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Least 10 Genetic Variants Are Associated,With Adult Onset ... In the most,comprehensive look at genetic risk factors ... working in close collaboration with two,other groups, has ... increased risk of diabetes and confirmed existence,of another ...
... 26, 2007 - Columbia,Laboratories, Inc. (NASDAQ: CBRX) ... data analysis of the recently-completed,randomized, placebo-controlled, double-blind ... gel) for the prevention of,preterm birth in ... than,35 weeks gestation has revealed a possible ...
Cached Medicine Technology:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 3Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 4Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 5Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 6Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 7Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... A short, preoperative team briefing prior to cardiac ... - improves communication and reduces errors and costs, according ... Mayo researchers believe this is the first such study ... preoperative briefings on specific disruptions to surgery. Disruptions were ...
... fires, elected officials and city managers gather to prepare ... The Los Angeles County Department of Public Health today ... at your Doorstep," designed to educate elected officials and ... More than one hundred participants attended the workshop from ...
... of the recently updated 2009 editions of two ... products industry. According to Market Scope, this is ... market. New anti-VEGF therapies are successfully treating vision-threatening ... been largely untreatable. Investigational devices are promising to ...
... Systems, Inc. today announced that the Frisco Independent ... Model 615 on four occasions during the first ... President of Operations.(Logo: http://www.newscom.com/cgi-bin/prnh/20051215/OXYSURELOGO ... in its first month of implementation, only solidifies ...
... Affordable Wristbands Access to Emergency Info LAHAINA, Hawaii, ... new product originally intended for athletes, yet appealing ... simple personal safety solution. The XtremeSportsID band is ... medical alert symbol, a unique 8-digit code, and ...
... software now availableINDIANAPOLIS, May 26 ProSolv CardioVascular, ... the commercial availability of Synapse(TM) ProSolv(R) ... integration with QLAB advanced quantification software from Philips ... been designed to enhance clinical workflow, help improve ...
Cached Medicine News:Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 3Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 4Health News:County and City Leaders Coordinate to Just Be Ready 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 3Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 4Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 2Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 3Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 4Health News:New Wristband May Save Lives 2Health News:New Wristband May Save Lives 3Health News:ProSolv Version 4.0.2 Makes Commercial Debut at ASE 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: